ArticleInternational journal of clinical and experimental medicine2015
Effects of combined thymosin and hydrocortisone on immune response in septic mice.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study is to investigate the effects of the thymosin α1 (Tα1) and hydrocortisone (HC) combination treatment on the immune responses in septic mice. According to different treatments, mice were divided into the control group (n = 18), the sepsis model group (n = 18), the Tα1 group (n = 18), the HC group (n = 18), and the Tα1+HC group (n = 18). Septic mouse model was established by the intraperitoneal injection of lipopolysaccharide (LPS). At 72 h after modeling, flow cytometry was used to analyze the dendritic cell (DC) numbers in peripheral blood and the expressions of MHC II and CD86. Tumor necrosis factor-α (TNF-α) level was measured by ELISA. Treatments of Tα1 and/or HC dramatically increased the survival rates of LPS-induced septic mice. Flow cytometry showed that, the DC numbers in peripheral blood were significantly decreased in the sepsis model group, which could be dramatically elevated by Tα1 treatment alone and in combination with HC (Tα1+HC). However, the DCs were undetectable in the HC group. In addition, the MHC II expression level was decreased in the sepsis model group, which was further declined in the Tα1 and Tα1+HC groups. The expression level of CD86 was elevated in the model group, which could be significantly down-regulated by the treatments of Tα1 and Tα1+HC. ELISA showed that, the peripheral blood TNF-α level in the HC group was lower than in the sepsis model group. Compared with the sepsis model group, the TNF-α levels were significantly elevated in the Tα1 and Tα1+HC groups. Tα1 and HC combination treatment could improve the immune function and regulate the inflammatory response to increase the survival rates of LPS-induced septic mice.
Indexed as
Identifiers
26550219PMC4612904W2407427889What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.